NATCOPHARM NATCO Pharma Ltd. — Smart-Money Activity, F&O Buildup & Bulk Deals
Sector: HealthcareLive setups screens NATCOPHARM is on right now — tap to see every stock matching
Smart Money Verdict synthesis of derivatives, deals, and promoter files
Analysis what the data is telling us about NATCOPHARM
NATCO Pharma Ltd. did not have meaningful F&O activity in the last completed session. That doesn't mean the stock is irrelevant — it just means the smart-money signals here come from cash markets and corporate disclosures, covered below.
There have been no notable bulk or block deals from FIIs, mutual funds, or insurance companies in NATCO Pharma Ltd. over the last 30 sessions.
Putting it together, the smart-money picture for NATCO Pharma Ltd. lacks a clear directional bias.
F&O Positioning EOD derivatives setup
Quote Details key metrics & weights
Technical Snapshot from 400 sessions of price history
Key Fundamentals headline ratios · Healthcare
Fundamental ratios sourced from public market data, refreshed periodically; verify against company filings before relying on them.
Institutional Deals last 30 sessions (bulk & block)
Insider & Promoter Filings last 60 days
Latest News recent coverage from Reuters, Simply Wall St, MT Newswires and others
NATCOPHARM — frequently asked questions
What is the NATCO Pharma Ltd. share price today?
NATCOPHARM is trading at ₹961.90 (+1.18% vs previous close), per the latest update on this page.
What is the P/E ratio of NATCO Pharma Ltd.?
NATCOPHARM (NATCO Pharma Ltd.) has a trailing twelve-month P/E ratio of 12.2.
What is the market cap of NATCO Pharma Ltd.?
NATCOPHARM has a market capitalisation of approximately ₹17,229 crore.
What is the ROE of NATCO Pharma Ltd.?
NATCOPHARM has a return on equity (ROE) of about 16.9%.
Is NATCOPHARM near its 52-week high?
NATCOPHARM is trading -21.6% from its 52-week high of ₹1,226.80 as of 2026-07-21.
What is the RSI of NATCOPHARM?
The 14-day RSI of NATCOPHARM is 52.8, which is considered neutral.
Is NATCOPHARM above its 200-day moving average?
NATCOPHARM is trading above its 200-DMA of ₹937.12 (+2.6% away).
Are FIIs or big investors buying NATCOPHARM?
Strota tracks every bulk and block deal in NATCOPHARM with named buyers and sellers, plus promoter and insider filings — the tables on this page list the most recent institutional activity as disclosed to the exchanges.